International Journal of Endocrinology and Metabolism

Published by: Kowsar

Tobacco Smoking: Findings from 20 Years of the Tehran Lipid and Glucose Study

Donna Parizadeh 1 , Amir Abbas Momenan 1 , * , Atieh Amouzegar 1 , 2 , Fereidoun Azizi 1 , 2 and Farzad Hadaegh 1 , **
Authors Information
1 Prevention of Metabolic Disorders Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
2 Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Corresponding Authors:
Article information
  • International Journal of Endocrinology and Metabolism: October 2018, 16 (4 (Suppl)); e84738
  • Published Online: October 31, 2018
  • Article Type: Review Article
  • Received: September 1, 2018
  • Revised: October 2, 2018
  • Accepted: October 7, 2018
  • DOI: 10.5812/ijem.84738

To Cite: Parizadeh D, Momenan A A, Amouzegar A, Azizi F, Hadaegh F. Tobacco Smoking: Findings from 20 Years of the Tehran Lipid and Glucose Study, Int J Endocrinol Metab. 2018 ; 16(4 (Suppl)):e84738. doi: 10.5812/ijem.84738.

Abstract
Copyright © 2018, International Journal of Endocrinology and Metabolism. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Context
2. Evidence Acquisition
3. Results
4. Discussion
Acknowledgements
References
  • 1. World Health Organization. Report on the global tobacco epidemic, 2008. The MPOWER package. 2008. Available from: http://www.who.int/tobacco/mpower/mpower_report_full_2008.pdf.
  • 2. Lim SS, Vos T, Flaxman AD, Danaei G, Shibuya K, Adair-Rohani H, et al. A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990-2010: A systematic analysis for the global burden of disease study 2010. Lancet. 2012;380(9859):2224-60. doi: 10.1016/S0140-6736(12)61766-8. [PubMed: 23245609]. [PubMed Central: PMC4156511].
  • 3. Mackay J EM. The tobacco Atlas. Geneva: World Health Organization; 2002.
  • 4. World Health Organization. WHO report on the global tobacco epidemic. 2017. Available from: http://www.who.int/tobacco/global_report/2017/appendix_II.pdf?ua=1.
  • 5. Meysamie A, Ghaletaki R, Haghazali M, Asgari F, Rashidi A, Khalilzadeh O, et al. Pattern of tobacco use among the Iranian adult population: Results of the national survey of risk factors of non-communicable diseases (SuRFNCD-2007). Tob Control. 2010;19(2):125-8. doi: 10.1136/tc.2009.030759. [PubMed: 20008159]. [PubMed Central: PMC2989156].
  • 6. Halimi L, Haghdoost AA, Mohammad Alizadeh S. Prevalence of cigarette smoking among Iranian women: A systematic review and meta-analysis. Med J Islam Repub Iran. 2013;27(3):132-40. [PubMed: 24791123]. [PubMed Central: PMC3917490].
  • 7. Mohammad-Alizadeh-Charandabi S, Mirghafourvand M, Tavananezhad N, Karkhaneh M. Prevalence of cigarette and water pipe smoking and their predictors among Iranian adolescents. Int J Adolesc Med Health. 2015;27(3):291-8. doi: 10.1515/ijamh-2014-0028. [PubMed: 25470603].
  • 8. Azizi F, Rahmani M, Emami H, Mirmiran P, Hajipour R, Madjid M, et al. Cardiovascular risk factors in an Iranian urban population: Tehran Lipid and Glucose Study (phase 1). Soz Praventivmed. 2002;47(6):408-26. [PubMed: 12643001].
  • 9. Azizi F, Emami H, Salehi P, Ghanbarian A, Mirmiran P, Mirbolooki M, et al. Cardiovascular risk factors in the elderly: The Tehran Lipid and Glucose Study. J Cardiovasc Risk. 2003;10(1):65-73. doi: 10.1097/01.hjr.0000050202.47754.1b. [PubMed: 12569239].
  • 10. Jahangiri-Noudeh Y, Akbarpour S, Lotfaliany M, Zafari N, Khalili D, Tohidi M, et al. Trends in cardiovascular disease risk factors in people with and without diabetes mellitus: A Middle Eastern cohort study. PLoS One. 2014;9(12). e112639. doi: 10.1371/journal.pone.0112639. [PubMed: 25461381]. [PubMed Central: PMC4251920].
  • 11. Eslami A, Lotfaliany M, Akbarpour S, Azizi F, Hadaegh F. Trend of cardiovascular risk factors in the older Iranian population: 2002-2014. Geriatr Gerontol Int. 2018;18(1):130-7. doi: 10.1111/ggi.13154. [PubMed: 28857406].
  • 12. Momenan AA, Etemadi A, Ghanbarian A, Azizi F . The rising prevalence of waterpipe smoking among Iranian adolescents: Tehran Lipid and Glucose Study. Proceedings of the 13th World Congress on Tobacco OR Health (WCTOH). Washington, DC, USA. 2006.
  • 13. Rostami Dovom M, Ramezani Tehrani F, Amiri P, Amirshekari G, Farahmand M, Azizi F. Main facilitators of smoking among young males in tehran: Tehran Lipid and Glucose Study. Iran Red Crescent Med J. 2014;16(9). e15429. doi: 10.5812/ircmj.15429. [PubMed: 25593726]. [PubMed Central: PMC4270672].
  • 14. Bozorgmanesh M, Hadaegh F, Mehrabi Y, Azizi F. A point-score system superior to blood pressure measures alone for predicting incident hypertension: Tehran Lipid and Glucose Study. J Hypertens. 2011;29(8):1486-93. doi: 10.1097/HJH.0b013e328348fdb2. [PubMed: 21720268].
  • 15. Derakhshan A, Sardarinia M, Khalili D, Momenan AA, Azizi F, Hadaegh F. Sex specific incidence rates of type 2 diabetes and its risk factors over 9 years of follow-up: Tehran Lipid and Glucose Study. PLoS One. 2014;9(7). e102563. doi: 10.1371/journal.pone.0102563. [PubMed: 25029368]. [PubMed Central: PMC4100911].
  • 16. Tohidi M, Hasheminia M, Mohebi R, Khalili D, Hosseinpanah F, Yazdani B, et al. Incidence of chronic kidney disease and its risk factors, results of over 10 year follow up in an Iranian cohort. PLoS One. 2012;7(9). e45304. doi: 10.1371/journal.pone.0045304. [PubMed: 23028919]. [PubMed Central: PMC3459968].
  • 17. Khalili D, Sheikholeslami FH, Bakhtiyari M, Azizi F, Momenan AA, Hadaegh F. The incidence of coronary heart disease and the population attributable fraction of its risk factors in Tehran: A 10-year population-based cohort study. PLoS One. 2014;9(8). e105804. doi: 10.1371/journal.pone.0105804. [PubMed: 25162590]. [PubMed Central: PMC4146560].
  • 18. Parizadeh D, Ramezankhani A, Momenan AA, Azizi F, Hadaegh F. Exploring risk patterns for incident ischemic stroke during more than a decade of follow-up: A survival tree analysis. Comput Methods Programs Biomed. 2017;147:29-36. doi: 10.1016/j.cmpb.2017.06.006. [PubMed: 28734528].
  • 19. Sardarinia M, Akbarpour S, Lotfaliany M, Bagherzadeh-Khiabani F, Bozorgmanesh M, Sheikholeslami F, et al. Risk factors for incidence of cardiovascular diseases and all-cause mortality in a middle eastern population over a decade follow-up: Tehran Lipid and Glucose Study. PLoS One. 2016;11(12). e0167623. doi: 10.1371/journal.pone.0167623. [PubMed: 27930696]. [PubMed Central: PMC5145170].
  • 20. Hadaegh F, Hasheminia M, Abdi H, Khalili D, Bozorgmanesh M, Arshi B, et al. Prehypertension tsunami: A decade follow-up of an iranian adult population. PLoS One. 2015;10(10). e0139412. doi: 10.1371/journal.pone.0139412. [PubMed: 26439847]. [PubMed Central: PMC4595371].
  • 21. Asgari S, Khalili D, Mehrabi Y, Kazempour-Ardebili S, Azizi F, Hadaegh F. Incidence and risk factors of isolated systolic and diastolic hypertension: A 10 year follow-up of the Tehran Lipids and Glucose Study. Blood Press. 2016;25(3):177-83. doi: 10.3109/08037051.2015.1116221. [PubMed: 26643588].
  • 22. Hadaegh F, Derakhshan A, Zafari N, Khalili D, Mirbolouk M, Saadat N, et al. Pre-diabetes tsunami: Incidence rates and risk factors of pre-diabetes and its different phenotypes over 9 years of follow-up. Diabet Med. 2017;34(1):69-78. doi: 10.1111/dme.13034. [PubMed: 26606421].
  • 23. Derakhshan A, Tohidi M, Hajebrahimi MA, Saadat N, Azizi F, Hadaegh F. Sex-specific incidence rates and risk factors of insulin resistance and beta-cell dysfunction: A decade follow-up in a Middle Eastern population. Diabet Med. 2017;34(2):245-52. doi: 10.1111/dme.13117. [PubMed: 26996519].
  • 24. Mirbolouk M, Derakhshan A, Charkhchi P, Guity K, Azizi F, Hadaegh F. Incidence and predictors of early adulthood pre-diabetes/type 2 diabetes, among Iranian adolescents: The Tehran Lipid and Glucose Study. Pediatr Diabetes. 2016;17(8):608-16. doi: 10.1111/pedi.12343. [PubMed: 26764014].
  • 25. Hadaegh F, Hasheminia M, Lotfaliany M, Mohebi R, Azizi F, Tohidi M. Incidence of metabolic syndrome over 9 years follow-up; the importance of sex differences in the role of insulin resistance and other risk factors. PLoS One. 2013;8(9). e76304. doi: 10.1371/journal.pone.0076304. [PubMed: 24086723]. [PubMed Central: PMC3785433].
  • 26. Amiri P, Deihim T, Taherian R, Karimi M, Gharibzadeh S, Asghari-Jafarabadi M, et al. Factors affecting gender differences in the association between health-related quality of life and metabolic syndrome components: Tehran Lipid and Glucose Study. PLoS One. 2015;10(12). e0143167. doi: 10.1371/journal.pone.0143167. [PubMed: 26625120]. [PubMed Central: PMC4666460].
  • 27. Ramezankhani A, Azizi F, Hadaegh F, Eskandari F. Sex-specific clustering of metabolic risk factors and their association with incident cardiovascular diseases: A population-based prospective study. Atherosclerosis. 2017;263:249-56. doi: 10.1016/j.atherosclerosis.2017.06.921. [PubMed: 28683364].
  • 28. Ehteshami-Afshar S, Momenan A, Hajshekholeslami F, Azizi F, Hadaegh F. The impact of smoking status on 9.3 years incidence of cardiovascular and all-cause mortality among Iranian men. Ann Hum Biol. 2014;41(3):249-54. doi: 10.3109/03014460.2013.853834. [PubMed: 24215537].
  • 29. Eslami A, Mozaffary A, Derakhshan A, Azizi F, Khalili D, Hadaegh F. Sex-specific incidence rates and risk factors of premature cardiovascular disease. A long term follow up of the Tehran Lipid and Glucose Study. Int J Cardiol. 2017;227:826-32. doi: 10.1016/j.ijcard.2016.10.037. [PubMed: 27829526].
  • 30. Ramezankhani A, Bagherzadeh-Khiabani F, Khalili D, Azizi F, Hadaegh F. A new look at risk patterns related to coronary heart disease incidence using survival tree analysis: 12 years longitudinal study. Sci Rep. 2017;7(1):3237. doi: 10.1038/s41598-017-03577-0. [PubMed: 28607472]. [PubMed Central: PMC5468345].
  • 31. Hadaegh F, Derakhshan A, Mozaffary A, Hasheminia M, Khalili D, Azizi F. Twelve-year cardiovascular and mortality risk in relation to smoking habits in type 2 diabetic and non-diabetic men: Tehran Lipid and Glucose Study. PLoS One. 2016;11(3). e0149780. doi: 10.1371/journal.pone.0149780. [PubMed: 26930192]. [PubMed Central: PMC4773225].
  • 32. Fahimfar N, Khalili D, Mohebi R, Azizi F, Hadaegh F. Risk factors for ischemic stroke; results from 9 years of follow-up in a population based cohort of Iran. BMC Neurol. 2012;12:117. doi: 10.1186/1471-2377-12-117. [PubMed: 23031547]. [PubMed Central: PMC3517457].
  • 33. Azizi F, Mirmiran P, Azadbakht L. Predictors of cardiovascular risk factors in Tehranian adolescents: Tehran Lipid and Glucose Study. Int J Vitam Nutr Res. 2004;74(5):307-12. doi: 10.1024/0300-9831.74.5.307. [PubMed: 15628667].
  • 34. Afsharian S, Akbarpour S, Abdi H, Sheikholeslami F, Moeini AS, Khalili D, et al. Risk factors for cardiovascular disease and mortality events in adults with type 2 diabetes - a 10-year follow-up: Tehran Lipid and Glucose Study. Diabetes Metab Res Rev. 2016;32(6):596-606. doi: 10.1002/dmrr.2776. [PubMed: 26787367].
  • 35. Baron JA, La Vecchia C, Levi F. The antiestrogenic effect of cigarette smoking in women. Am J Obstet Gynecol. 1990;162(2):502-14. doi: 10.1016/0002-9378(90)90420-C. [PubMed: 2178432].
  • 36. Farahmand M, Tehrani FR, Pourrajabi L, Najafi M, Azizi F. Factors associated with menopausal age in Iranian women: Tehran Lipid and Glucose Study. J Obstet Gynaecol Res. 2013;39(4):836-41. doi: 10.1111/j.1447-0756.2012.02050.x. [PubMed: 23279558].
  • 37. Ramezani Tehrani F, Mirmiran P, Gholami R, Moslehi N, Azizi F. Factors influencing menarcheal age: results from the cohort of Tehran Lipid and Glucose Study. Int J Endocrinol Metab. 2014;12(3). e16130. doi: 10.5812/ijem.16130. [PubMed: 25237321]. [PubMed Central: PMC4166004].
  • 38. Kazemijaliseh H, Ramezani Tehrani F, Behboudi-Gandevani S, Hosseinpanah F, Khalili D, Azizi F. The prevalence and causes of primary infertility in Iran: A population-based study. Glob J Health Sci. 2015;7(6):226-32. doi: 10.5539/gjhs.v7n6p226. [PubMed: 26153187]. [PubMed Central: PMC4803880].
  • 39. Kazemijaliseh H, Ramezani Tehrani F, Behboudi-Gandevani S, Khalili D, Hosseinpanah F, Azizi F. A population-based study of the prevalence of abnormal uterine bleeding and its related factors among Iranian reproductive-age women: An updated data. Arch Iran Med. 2017;20(9):558-63. [PubMed: 29048917].
  • 40. Mehran L, Amouzgar A, Delshad H, Azizi F. The association of cigarette smoking with serum TSH concentration and thyroperoxidase antibody. Exp Clin Endocrinol Diabetes. 2012;120(2):80-3. doi: 10.1055/s-0031-1285910. [PubMed: 21915816].
  • 41. Amouzegar A, Ghaemmaghami Z, Beigy M, Gharibzadeh S, Mehran L, Tohidi M, et al. Natural course of euthyroidism and clues for early diagnosis of thyroid dysfunction: Tehran Thyroid Study. Thyroid. 2017;27(5):616-25. doi: 10.1089/thy.2016.0409. [PubMed: 28071990].
  • 42. Asghari G, Mirmiran P, Hosseni-Esfahani F, Nazeri P, Mehran M, Azizi F. Dietary quality among Tehranian adults in relation to lipid profile: findings from the Tehran Lipid and Glucose Study. J Health Popul Nutr. 2013;31(1):37-48. doi: 10.3329/jhpn.v31i1.14747. [PubMed: 23617203]. [PubMed Central: PMC3702357].
  • 43. Momenan AA, Delshad M, Mirmiran P, Ghanbarian A, Azizi F. Leisure time physical activity and its determinants among adults in Tehran: Tehran Lipid and Glucose Study. Int J Prev Med. 2011;2(4):243-51. [PubMed: 22174964]. [PubMed Central: PMC3237267].
  • 44. Ghasemi A, Syedmoradi L, Momenan AA, Zahediasl S, Azizi F. The influence of cigarette and qalyan (hookah) smoking on serum nitric oxide metabolite concentration. Scand J Clin Lab Invest. 2010;70(2):116-21. doi: 10.3109/00365511003611282. [PubMed: 20156035].
  • 45. Azizi F, Ghanbarian A, Momenan AA, Hadaegh F, Mirmiran P, Hedayati M, et al. Prevention of non-communicable disease in a population in nutrition transition: Tehran Lipid and Glucose Study phase II. Trials. 2009;10:5. doi: 10.1186/1745-6215-10-5. [PubMed: 19166627]. [PubMed Central: PMC2656492].
  • 46. Harati H, Hadaegh F, Momenan AA, Ghanei L, Bozorgmanesh MR, Ghanbarian A, et al. Reduction in incidence of type 2 diabetes by lifestyle intervention in a middle eastern community. Am J Prev Med. 2010;38(6):628-636 e1. doi: 10.1016/j.amepre.2010.03.003. [PubMed: 20494239].
  • 47. Global Youth Tabacco Survey Collaborative G. Tobacco use among youth: A cross country comparison. Tob Control. 2002;11(3):252-70. doi: 10.1136/tc.11.3.252. [PubMed: 12198280]. [PubMed Central: PMC1759013].
  • 48. Kelishadi R, Ardalan G, Gheiratmand R, Majdzadeh R, Delavari A, Heshmat R, et al. Smoking behavior and its influencing factors in a national-representative sample of Iranian adolescents: CASPIAN Study. Prev Med. 2006;42(6):423-6. doi: 10.1016/j.ypmed.2006.03.001. [PubMed: 16624397].
  • 49. World Health Organization. WHO report on the global tobacco epidemic, 2017. Country profile Iran (Islamic Republic of). 2017. Available from: http://www.who.int/tobacco/surveillance/policy/country_profile/irn.pdf.
  • 50. World Health Organization. Guideline for controlling and monitoring. The Tobacco Epidemic. 1998. Available from: http://www.who.int/iris/handle/10665/42049.
  • 51. Sarraf-Zadegan N, Boshtam M, Shahrokhi S, Naderi GA, Asgary S, Shahparian M, et al. Tobacco use among Iranian men, women and adolescents. Eur J Public Health. 2004;14(1):76-8. doi: 10.1093/eurpub/14.1.76. [PubMed: 15080396].
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments